Valuation : BioNTech SE

Market Cap 2.09TCr 2.42TCr 1.98TCr 1.79TCr 3.36TCr 2,31300Cr 3.38TCr 23TCr 9.02TCr 1,17700Cr 9.09TCr 8.9TCr 3,71900Cr P/E 2026 *
-14.6x
P/E 2027 * -15.3x
Enterprise Value 949.61Cr 1.1TCr 899.15Cr 814.99Cr 1.53TCr 1,05300Cr 1.54TCr 11TCr 4.11TCr 54TCr 4.14TCr 4.05TCr 1,69300Cr EV / Sales 2026 *
5.26x
EV / Sales 2027 * 5.98x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week-6.16%
Current month-4.87%
1 month+3.23%
3 months+10.74%
6 months+14.48%
Current year+2.09%
1 week 82.7
Extreme 82.7
90.25
1 month 78.4
Extreme 78.4
103.1
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
335.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.66%-6.16%-5.14%-25.93% 2.42TCr
-2.11%-3.44%+41.04%+98.48% 6.82TCr
-0.23%-6.42%+30.19%+76.15% 6.22TCr
+1.67%+2.16%-11.32%+392.80% 2.78TCr
-1.05%-7.30%+25.00%+12.31% 2.49TCr
+0.34%-5.98%-4.23%-19.48% 2.42TCr
+0.43%-4.78%+18.26%-20.61% 1.94TCr
-3.03%-5.19%+192.88%+340.13% 1.73TCr
-1.94%-6.36%-7.05%+516.16% 1.45TCr
-2.28%-5.09%+48.86%+153.82% 1.42TCr
Average -0.91%-3.96%+32.85%+152.38% 3.03TCr
Weighted average by Cap. -0.86%-3.80%+30.45%+123.67%

Financials

2026 *2027 *
Net sales 180.67Cr 209.69Cr 171.07Cr 155.05Cr 290.89Cr 20TCr 292.37Cr 2.03TCr 781.29Cr 10TCr 787.5Cr 770.22Cr 32TCr 181.3Cr 210.42Cr 171.67Cr 155.6Cr 291.91Cr 20TCr 293.39Cr 2.04TCr 784.03Cr 10TCr 790.26Cr 772.92Cr 32TCr
Net income -137.79Cr -159.92Cr -130.46Cr -118.25Cr -221.85Cr -15TCr -222.97Cr -1.55TCr -595.86Cr -7.77TCr -600.59Cr -587.41Cr -25TCr -130.86Cr -151.88Cr -123.91Cr -112.31Cr -210.7Cr -15TCr -211.77Cr -1.47TCr -565.92Cr -7.38TCr -570.41Cr -557.9Cr -23TCr
Net Debt -1.14TCr -1.32TCr -1.08TCr -975.69Cr -1.83TCr -1,26100Cr -1.84TCr -13TCr -4.92TCr -64TCr -4.96TCr -4.85TCr -2,02600Cr -1TCr -1.16TCr -949.79Cr -860.89Cr -1.62TCr -1,11200Cr -1.62TCr -11TCr -4.34TCr -57TCr -4.37TCr -4.28TCr -1,78800Cr
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
12/26/12 83.55 +0.66%
10/26/10 €83.00 -1.66%
09/26/09 €84.40 -1.00%
08/26/08 €85.25 -4.96%
07/26/07 €89.70 +0.50%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.90EUR
Average target price
102.47EUR
Spread / Average Target
+23.60%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!